12:00 AM
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Rencarex girentuximab: Additional Phase III data

A subgroup analysis of the double-blind, international Phase III ARISER trial in 864 clear cell RCC patients showed that IV Rencarex significantly improved median DFS in patients with high tumor levels of CAIX compared to both placebo and to Rencarex-treated patients with low tumor levels of CAIX. Wilex declined to disclose the proportion of patients in the trial with high and low levels of CAIX. ARISER evaluated once-weekly Rencarex...

Read the full 322 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >